Whittier Trust Co. increased its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 4.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 34,219 shares of the medical research company’s stock after purchasing an additional 1,334 shares during the quarter. Whittier Trust Co.’s holdings in Amgen were worth $6,380,000 as of its most recent filing with the SEC.
Several other hedge funds also recently bought and sold shares of the stock. Baker Ellis Asset Management LLC acquired a new stake in shares of Amgen in the third quarter worth $108,000. TrimTabs Asset Management LLC lifted its stake in shares of Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after buying an additional 288 shares during the last quarter. Phocas Financial Corp. bought a new position in Amgen during the second quarter worth $110,000. Jackson Grant Investment Advisers Inc. increased its position in Amgen by 0.8% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after acquiring an additional 5 shares during the period. Finally, Omnia Family Wealth LLC increased its position in Amgen by 25.3% during the second quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after acquiring an additional 147 shares during the period. Institutional investors and hedge funds own 78.46% of the company’s stock.
Shares of Amgen, Inc. (AMGN) traded up $3.08 during trading hours on Friday, hitting $185.04. 3,082,800 shares of the stock traded hands, compared to its average volume of 2,720,000. Amgen, Inc. has a 52 week low of $150.38 and a 52 week high of $191.10. The company has a debt-to-equity ratio of 1.05, a current ratio of 6.07 and a quick ratio of 5.72. The firm has a market cap of $134,320.00, a P/E ratio of 16.72, a PEG ratio of 2.66 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The business had revenue of $5.77 billion for the quarter, compared to the consensus estimate of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The firm’s quarterly revenue was down .7% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.02 EPS. equities research analysts predict that Amgen, Inc. will post 12.71 earnings per share for the current fiscal year.
Amgen declared that its board has initiated a share repurchase plan on Wednesday, October 25th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to repurchase shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be given a dividend of $1.32 per share. This is an increase from Amgen’s previous quarterly dividend of $1.15. The ex-dividend date is Wednesday, February 14th. This represents a $5.28 annualized dividend and a yield of 2.85%. Amgen’s dividend payout ratio is 41.55%.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $171.58, for a total transaction of $261,659.50. Following the transaction, the executive vice president now directly owns 57,631 shares in the company, valued at approximately $9,888,326.98. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Carbonnel Francois De sold 4,000 shares of the company’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 7,050 shares of company stock worth $1,225,765. 0.19% of the stock is owned by corporate insiders.
AMGN has been the topic of a number of research reports. Vetr lowered shares of Amgen from a “buy” rating to a “hold” rating and set a $184.25 target price on the stock. in a research report on Wednesday, January 3rd. Mizuho reaffirmed a “buy” rating and set a $198.00 target price (up previously from $183.00) on shares of Amgen in a research report on Thursday, September 28th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Amgen in a research report on Tuesday, January 2nd. BMO Capital Markets reaffirmed a “hold” rating and set a $198.00 target price on shares of Amgen in a research report on Friday, October 20th. Finally, Jefferies Group reissued a “buy” rating and issued a $200.00 price target on shares of Amgen in a report on Monday, September 25th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $190.15.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.